Tozorakimab: a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction
I. Scott (Cambridge, United Kingdom), E. England (Cambridge, United Kingdom), D. Rees (Cambridge, United Kingdom), T. Erngren (Gothenburg, Sweden), C. Chaillan Huntington (Cambridge, United Kingdom), K. Houslay (Cambridge, United Kingdom), D. Sims (Gaithersburg, United States), C. Hollins (Cambridge, United Kingdom), E. Hinchy (Cambridge, United Kingdom), C. Colley (Cambridge, United Kingdom), D. Corkill (Cambridge, United Kingdom), E. Cohen (Cambridge, United Kingdom)
Source: International Congress 2022 – Clinical and translational studies of asthma and COPD: novel mechanisms
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Scott (Cambridge, United Kingdom), E. England (Cambridge, United Kingdom), D. Rees (Cambridge, United Kingdom), T. Erngren (Gothenburg, Sweden), C. Chaillan Huntington (Cambridge, United Kingdom), K. Houslay (Cambridge, United Kingdom), D. Sims (Gaithersburg, United States), C. Hollins (Cambridge, United Kingdom), E. Hinchy (Cambridge, United Kingdom), C. Colley (Cambridge, United Kingdom), D. Corkill (Cambridge, United Kingdom), E. Cohen (Cambridge, United Kingdom). Tozorakimab: a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. 2254
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|